Item 8.01. Other Events.
On May 28, 2009, OSI Pharmaceuticals, Inc. ("OSI"), together with Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc., and Roche, announced the initiation of a Phase III trial examining NexavarŽ(sorafenib) tablets in combination with TarcevaŽ (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma or primary liver cancer. A copy of OSI's press release, dated May 28, 2009, is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On May 30, 2009, OSI announced that its U.S. partner for Tarceva, Genentech, Inc., a wholly-owned member of the Roche Group, informed OSI of detailed results from a Genentech conducted Phase III study (ATLAS). A copy of OSI's press release, dated May 30, 2009, is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.

Exhibit No. Description 99.1 Press release dated May 28, 2009. 99.2 Press release dated May 30, 2009.

-2-

---

Table of Contents